161 related articles for article (PubMed ID: 14750833)
1. A new strategy for the construction of the imidazo[1,5-a]quinoxalin-4-one ring system and its application to the efficient synthesis of BMS-238497, a novel and potent Lck inhibitor.
Chen BC; Zhao R; Bednarz MS; Wang B; Sundeen JE; Barrish JC
J Org Chem; 2004 Feb; 69(3):977-9. PubMed ID: 14750833
[TBL] [Abstract][Full Text] [Related]
2. Regioselective, unconventional Pictet-Spengler cyclization strategy toward the synthesis of benzimidazole-linked imidazoquinoxalines on a soluble polymer support.
Chen CH; Kuo J; Yellol GS; Sun CM
Chem Asian J; 2011 Jun; 6(6):1557-65. PubMed ID: 21472995
[TBL] [Abstract][Full Text] [Related]
3. Discovery and initial SAR of imidazoquinoxalines as inhibitors of the Src-family kinase p56(Lck).
Chen P; Norris D; Iwanowicz EJ; Spergel SH; Lin J; Gu HH; Shen Z; Wityak J; Lin TA; Pang S; De Fex HF; Pitt S; Shen DR; Doweyko AM; Bassolino DA; Roberge JY; Poss MA; Chen BC; Schieven GL; Barrish JC
Bioorg Med Chem Lett; 2002 May; 12(10):1361-4. PubMed ID: 11992777
[TBL] [Abstract][Full Text] [Related]
4. Imidazoquinoxaline Src-family kinase p56Lck inhibitors: SAR, QSAR, and the discovery of (S)-N-(2-chloro-6-methylphenyl)-2-(3-methyl-1-piperazinyl)imidazo- [1,5-a]pyrido[3,2-e]pyrazin-6-amine (BMS-279700) as a potent and orally active inhibitor with excellent in vivo antiinflammatory activity.
Chen P; Doweyko AM; Norris D; Gu HH; Spergel SH; Das J; Moquin RV; Lin J; Wityak J; Iwanowicz EJ; McIntyre KW; Shuster DJ; Behnia K; Chong S; de Fex H; Pang S; Pitt S; Shen DR; Thrall S; Stanley P; Kocy OR; Witmer MR; Kanner SB; Schieven GL; Barrish JC
J Med Chem; 2004 Aug; 47(18):4517-29. PubMed ID: 15317463
[TBL] [Abstract][Full Text] [Related]
5. Discovery of 2-phenylamino-imidazo[4,5-h]isoquinolin-9-ones: a new class of inhibitors of lck kinase.
Snow RJ; Cardozo MG; Morwick TM; Busacca CA; Dong Y; Eckner RJ; Jacober S; Jakes S; Kapadia S; Lukas S; Panzenbeck M; Peet GW; Peterson JD; Prokopowicz AS; Sellati R; Tolbert RM; Tschantz MA; Moss N
J Med Chem; 2002 Aug; 45(16):3394-405. PubMed ID: 12139450
[TBL] [Abstract][Full Text] [Related]
6. New imidazo[1,2-a]quinoxaline derivatives: synthesis and in vitro activity against human melanoma.
Deleuze-Masquefa C; Moarbess G; Khier S; David N; Gayraud-Paniagua S; Bressolle F; Pinguet F; Bonnet PA
Eur J Med Chem; 2009 Sep; 44(9):3406-11. PubMed ID: 19278757
[TBL] [Abstract][Full Text] [Related]
7. SVM model for virtual screening of Lck inhibitors.
Liew CY; Ma XH; Liu X; Yap CW
J Chem Inf Model; 2009 Apr; 49(4):877-85. PubMed ID: 19267483
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and SAR of novel imidazoquinoxaline-based Lck inhibitors: improvement of cell potency.
Chen P; Iwanowicz EJ; Norris D; Gu HH; Lin J; Moquin RV; Das J; Wityak J; Spergel SH; de Fex H; Pang S; Pitt S; Shen DR; Schieven GL; Barrish JC
Bioorg Med Chem Lett; 2002 Nov; 12(21):3153-6. PubMed ID: 12372522
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of imidazo[1,5,4-de]quinoxalin-9-ones, benzimidazole analogues of pyrroloiminoquinone marine natural products.
Labarbera DV; Skibo EB
Bioorg Med Chem; 2005 Jan; 13(2):387-95. PubMed ID: 15598560
[TBL] [Abstract][Full Text] [Related]
10. Development of N-4,6-pyrimidine-N-alkyl-N'-phenyl ureas as orally active inhibitors of lymphocyte specific tyrosine kinase.
Maier JA; Brugel TA; Sabat M; Golebiowski A; Laufersweiler MJ; VanRens JC; Hopkins CR; De B; Hsieh LC; Brown KK; Easwaran V; Janusz MJ
Bioorg Med Chem Lett; 2006 Jul; 16(14):3646-50. PubMed ID: 16682201
[TBL] [Abstract][Full Text] [Related]
11. An efficient one-pot synthesis of benzo[4,5]imidazo[1,2-a]quinoxalines via copper-catalyzed process.
Huang A; Chen Y; Zhou Y; Guo W; Wu X; Ma C
Org Lett; 2013 Nov; 15(21):5480-3. PubMed ID: 24147823
[TBL] [Abstract][Full Text] [Related]
12. Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity.
Martin MW; Newcomb J; Nunes JJ; Boucher C; Chai L; Epstein LF; Faust T; Flores S; Gallant P; Gore A; Gu Y; Hsieh F; Huang X; Kim JL; Middleton S; Morgenstern K; Oliveira-dos-Santos A; Patel VF; Powers D; Rose P; Tudor Y; Turci SM; Welcher AA; Zack D; Zhao H; Zhu L; Zhu X; Ghiron C; Ermann M; Johnston D; Saluste CG
J Med Chem; 2008 Mar; 51(6):1637-48. PubMed ID: 18278858
[TBL] [Abstract][Full Text] [Related]
13. The development of novel 1,2-dihydro-pyrimido[4,5-c]pyridazine based inhibitors of lymphocyte specific kinase (Lck).
Sabat M; Vanrens JC; Brugel TA; Maier J; Laufersweiler MJ; Golebiowski A; De B; Easwaran V; Hsieh LC; Rosegen J; Berberich S; Suchanek E; Janusz MJ
Bioorg Med Chem Lett; 2006 Aug; 16(16):4257-61. PubMed ID: 16757169
[TBL] [Abstract][Full Text] [Related]
14. Discovery of novel 2-(aminoheteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinase p56(Lck) inhibitors.
Chen P; Norris D; Das J; Spergel SH; Wityak J; Leith L; Zhao R; Chen BC; Pitt S; Pang S; Shen DR; Zhang R; De Fex HF; Doweyko AM; McIntyre KW; Shuster DJ; Behnia K; Schieven GL; Barrish JC
Bioorg Med Chem Lett; 2004 Dec; 14(24):6061-6. PubMed ID: 15546730
[TBL] [Abstract][Full Text] [Related]
15. Molecular design, synthesis, and structure-Activity relationships leading to the potent and selective p56(lck) inhibitor BMS-243117.
Das J; Lin J; Moquin RV; Shen Z; Spergel SH; Wityak J; Doweyko AM; DeFex HF; Fang Q; Pang S; Pitt S; Shen DR; Schieven GL; Barrish JC
Bioorg Med Chem Lett; 2003 Jul; 13(13):2145-9. PubMed ID: 12798323
[TBL] [Abstract][Full Text] [Related]
16. Efficient synthesis of 5,6-dihydroxyindole dimers, key eumelanin building blocks, by a unified o-ethynylaniline-based strategy for the construction of 2-linked biindolyl scaffolds.
Capelli L; Manini P; Pezzella A; Napolitano A; d'Ischia M
J Org Chem; 2009 Sep; 74(18):7191-4. PubMed ID: 19663515
[TBL] [Abstract][Full Text] [Related]
17. Synthesis of novel KDR kinase inhibitors through catalytic reductive cyclization of o-nitrobenzylcarbonyl compounds.
Wong A; Kuethe JT; Davies IW; Hughes DL
J Org Chem; 2004 Oct; 69(22):7761-4. PubMed ID: 15498012
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of potential bisubstrate inhibitors of protein farnesyltransferase. Design and synthesis of functionalized imidazoles.
de Figueiredo RM; Coudray L; Dubois J
Org Biomol Chem; 2007 Oct; 5(20):3299-309. PubMed ID: 17912382
[TBL] [Abstract][Full Text] [Related]
19. Identification of non-phosphate-containing small molecular weight inhibitors of the tyrosine kinase p56 Lck SH2 domain via in silico screening against the pY + 3 binding site.
Huang N; Nagarsekar A; Xia G; Hayashi J; MacKerell AD
J Med Chem; 2004 Jul; 47(14):3502-11. PubMed ID: 15214778
[TBL] [Abstract][Full Text] [Related]
20. Synthetic methodology utilized to prepare substituted imidazole p38 MAP kinase inhibitors.
Murry JA
Curr Opin Drug Discov Devel; 2003 Nov; 6(6):945-65. PubMed ID: 14758763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]